170 related articles for article (PubMed ID: 38658974)
21. Subcellular localization and RNP formation of IGF2BPs (IGF2 mRNA-binding proteins) is modulated by distinct RNA-binding domains.
Wächter K; Köhn M; Stöhr N; Hüttelmaier S
Biol Chem; 2013 Aug; 394(8):1077-90. PubMed ID: 23640942
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic regulation of mRNA N6-methyladenosine modifications in mammalian gametogenesis.
Fang F; Wang X; Li Z; Ni K; Xiong C
Mol Hum Reprod; 2021 May; 27(5):. PubMed ID: 33823008
[TBL] [Abstract][Full Text] [Related]
23. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
[TBL] [Abstract][Full Text] [Related]
24. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
[TBL] [Abstract][Full Text] [Related]
25. A Tale of Loops and Tails: The Role of Intrinsically Disordered Protein Regions in R-Loop Recognition and Phase Separation.
Dettori LG; Torrejon D; Chakraborty A; Dutta A; Mohamed M; Papp C; Kuznetsov VA; Sung P; Feng W; Bah A
Front Mol Biosci; 2021; 8():691694. PubMed ID: 34179096
[TBL] [Abstract][Full Text] [Related]
26. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
[No Abstract] [Full Text] [Related]
27. Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel.
Shen Z; Zhou L; Zhang C; Xu J
Cancer Lett; 2020 Jan; 468():88-101. PubMed ID: 31593800
[TBL] [Abstract][Full Text] [Related]
28. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
[TBL] [Abstract][Full Text] [Related]
29. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
[TBL] [Abstract][Full Text] [Related]
30. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer.
Zhang C; Zhang M; Ge S; Huang W; Lin X; Gao J; Gong J; Shen L
Cancer Med; 2019 Aug; 8(10):4766-4781. PubMed ID: 31243897
[TBL] [Abstract][Full Text] [Related]
31. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
32. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
[TBL] [Abstract][Full Text] [Related]
33. Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
Yu W; Li J; Wang Q; Wang B; Zhang L; Liu Y; Tang M; Xu G; Yang Z; Wang X; Zhang J; Liu Y; Shi G
Prostate; 2019 Aug; 79(11):1304-1315. PubMed ID: 31212367
[TBL] [Abstract][Full Text] [Related]
34. m
Lang C; Yin C; Lin K; Li Y; Yang Q; Wu Z; Du H; Ren D; Dai Y; Peng X
Clin Transl Med; 2021 Jun; 11(6):e426. PubMed ID: 34185427
[TBL] [Abstract][Full Text] [Related]
35. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
36. Systematic Investigation of mRNA
Jiang M; Lu Y; Duan D; Wang H; Man G; Kang C; Abulimiti K; Li Y
Dis Markers; 2020; 2020():8833438. PubMed ID: 33273988
[TBL] [Abstract][Full Text] [Related]
37. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
[TBL] [Abstract][Full Text] [Related]
38. EIF4A3-Induced circARHGAP29 Promotes Aerobic Glycolysis in Docetaxel-Resistant Prostate Cancer through IGF2BP2/c-Myc/LDHA Signaling.
Jiang X; Guo S; Wang S; Zhang Y; Chen H; Wang Y; Liu R; Niu Y; Xu Y
Cancer Res; 2022 Mar; 82(5):831-845. PubMed ID: 34965937
[TBL] [Abstract][Full Text] [Related]
39. N(6)-adenosine-methyltransferase-14 promotes glioma tumorigenesis by repressing argininosuccinate synthase 1 expression in an m6A-dependent manner.
Miao YQ; Chen W; Zhou J; Shen Q; Sun Y; Li T; Wang SC
Bioengineered; 2022 Jan; 13(1):1858-1871. PubMed ID: 35012429
[TBL] [Abstract][Full Text] [Related]
40. SPOP mutation induces DNA methylation via stabilizing GLP/G9a.
Zhang J; Gao K; Xie H; Wang D; Zhang P; Wei T; Yan Y; Pan Y; Ye W; Chen H; Shi Q; Li Y; Zhao SM; Hou X; Weroha SJ; Wang Y; Zhang J; Karnes RJ; He HH; Wang L; Wang C; Huang H
Nat Commun; 2021 Sep; 12(1):5716. PubMed ID: 34588438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
